In this study, using gene expression and clinical data from the POETIC trial [14], we confirmed in an independent dataset that MKShi/ERSlo tumours respond poorly to neoadjuvant endocrine therapy, as evidenced by the persistently high Ki67 values after neoadjuvant AI therapy. This evidence concerns the gene MKI67 and neoplasm.